Kyoto University has taken part in an $8.1m series A round for Alphanavi Pharma, which is developing drugs for neuropathic pain that will partly be based on the institution's research.
Kyoto University Innovation Capital, the university venture fund operated by Kyoto University, has joined partners including pharmaceutical firm Sumitomo Dainippon Pharma to form a Japan-based neuropathic pain treatment developer called AlphaNavi Pharma.
The spinout is equipped with more than ¥900m ($8.1m) in series A funding from a consortium that includes SMBC Venture Capital, Shinsei Capital Partners and Chushin Venture Capital, subsidiaries of financial services firms Sumitomo Mitsui Banking Corp, Shinsei Bank and Kyoto Chuo Shinkin Bank, as well as…
